Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Liked2Thinkon Mar 22, 2022 10:38am
78 Views
Post# 34534280

RE:Question

RE:Question xmas is always a go to excuse.

Even though they "were working together with CARE" long before they actually bought them (Tripps words!) they will still use the excuse that they bought CARE this year and its tough to integrate two tiny tiny companies in a calendar year.  The accouting will be a disaster as it always is.  Didnt they switch companies in that regard again this year so there is another go to excuse for them.  I think they like to switch each year so they can have that excuse locked and loaded.

Tripp also said CARE does $4M in revenue a year without STagezero so if they cant do $1M in one quarter together then that is just another lie of many Tripp has said and put out there and a clear sign this "company" will not succeed at anything but robbing people out of their hard earned money.

They will be either late in reporting or have massive issues that are "beyond their control".  I dont know what the geniuses expect when they always wait until the last possible second to put news out there.  If they hadnt had done that back on Apr 1 and instead just put out a NR stating Aristotle had been released and then put out the NR about buying CARE a week later the SP would be down but not at the pathetic 18 cents well lets face it .175 it will be today.

I dont see revenue being over $1M and costs will be the highest they have ever been.  They are almost out of money from the last pathetic PP that they still have never put on their social media.

All you shareholders will get after a year of them releasing aristotle will be another $crew job in the form of another pathetic PP and a vote to do a RS if the almighty Tripp deams it so later on in the year.
<< Previous
Bullboard Posts
Next >>